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Vascular endothelial growth factor (VEGF) is reported to be a potent pro-angiogenic factor
that plays a pivotal role in both physiological and pathological angiogenesis. Royal jelly (RJ)
is a honeybee product containing various proteins, sugars, lipids, vitamins and free amino acids.
10-Hydroxy-2-decenoic acid (10HDA), a major fatty acid component of RJ, is known to have
various pharmacological effects; its antitumor activity being especially noteworthy. However,
the mechanism underlying this effect is unclear. We examined the effect of 10HDA on VEGF-
induced proliferation, migration and tube formation in human umbilical vein endothelial cells
(HUVECs). Our findings showed that, 10HDA at 20mM or more significantly inhibited such
proliferation, migration and tube formation. Similarly, 10mM GM6001, a matrix metallopro-
tease inhibitor, prevented VEGF-induced migration and tube formation. These findings indicate
that 10HDA exerts an inhibitory effect on VEGF-induced angiogenesis, partly by inhibiting
both cell proliferation and migration. Further experiments will be needed to clarify the detailed
mechanism.
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Introduction
Angiogenesis, the formation of new blood vessels from
the pre-existing vasculature, is a highly regulated process
that is essential for the development of multicellular
organisms (1,2). In the adult, angiogenesis is normally
restricted and is predominantly associated with female
reproductive functions and wound healing (3,4). Vascular
endothelial growth factor (VEGF) is a key regulator of
normal and pathological angiogenesis (5–7). At the cell-
ular level, VEGF stimulation drives multiple responses,
including endothelial cell proliferation, migration,
survival and permeability (8). Loss of regulation of
angiogenesis, resulting in uncontrolled and excessive
neovascularization, contributes to the development of
many pathologies, including retinopathies, rheumatoid
arthritis and tumor growth (9,10).
Royal jelly (RJ), the exclusive food of the larva of
the queen honeybee (Apis mellifera), is secreted from the
hypopharyngeal and mandibular glands of the worker
honeybees mainly between the sixth and twelfth days of
their life (11). RJ has been demonstrated to possess
several pharmacological activities in experimental ani-
mals, including vasodilator and hypotensive activities
(12), growth rate increasing activity (13), a disinfectant
action (14), antitumor activity (15–17), antihypercholes-
terolemic activity (18) and anti-inflammatory activity
(19). Chemical composition analysis has shown that RJ
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properly cited.consists mainly of proteins, sugars, lipids, vitamins and
free amino acids (20,21). 10HDA, a major fatty acid
component of RJ, has many pharmacological activities,
such as antitumor activity (22), size- and lipogenesis-
inhibiting activity toward the hamster ear sebaceous
gland (23), collagen production promoting activity (24)
and antibiotic activity (25). As a consequence, RJ is
widely used in commercial medical products, health foods
and cosmetics in many countries. However, the mecha-
nisms underlying these activities of RJ, especially the
antitumor activity, remain unknown.
Matrix metalloproteinase (MMP) is required for migra-
tion and invasion by normal and tumor cells. We initially
utilized the MMP inhibitor GM6001 to assess the effect
of MMP inhibitors on thymocyte development. GM6001,
a hydroxylamine-based inhibitor which inhibits many
MMP with a Ki in the low nanomolar range, has been
reported to reduce the migration of many kinds of cells
(26). We used GM6001 as a positive control in the
present study.
The purpose here was to evaluate the functional role of
10HDA on human pathology. A number of compounds,
including valproic acid (27), sodium butyrate (28) and
isomers of conjugated linoleic acid (29), are known to be
angiogenesis inhibitors. Here, we examined the effects of
10HDA on VEGF-induced angiogenesis in human
umbilical vein endothelial cells (HUVECs).
Methods
Cells and Chemicals
HUVECs, fibroblast cells, endothelial cell basal medium
(HuMedia-EB2), fetal bovine serum (FBS), gentamycin,
amphotericin B, endothelial growth factors (hEGF,
hydrocortisone, hFGF-B and heparin), VEGF, mouse
antihuman CD31 antibody, goat antimouse IgG alkaline
phosphatase-conjugated antibody, 5-bromo-4-chloro-
3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT)
and angiogenesis growth medium were purchased from
Kurabo (Osaka, Japan). 10HDA was purchased from
API Co. Ltd (Gifu, Japan), which was refined from RJ in
China. GM6001 was from SIGMA-Aldrich (St. Louis,
MO, USA). Collagen type I was from Kanda Gelatin
Tech (Osaka, Japan). Cell Culture Kit-8 was from
Dojindo (Kumamoto, Japan).
Cell Cultures
The HUVEC line is the cell model most commonly used
to analyze the effects of various drugs and reagents on
angiogenesis related to tumor growth and metastasis
(30–32). HUVECs were cultured in HuMedia-EB2
(Kurabo) supplemented with 2% (v/v) FBS, 50mg/ml
gentamycin, 50ng/ml amphotericin B, and endothelial
growth factors (10ng/ml hEGF, 1mg/ml hydrocortisone,
5ng/ml hFGF-B and 10mg/ml heparin) at 37Ci na
humidified atmosphere of 5% CO2.
Tube-Formation Assay
To evaluate tube formation by endothelial cells, a
HUVECs in vitro angiogenesis kit (Kurabo) was used.
HUVECs and fibroblasts were co-cultured in angiogen-
esis growth medium supplemented with VEGF (10ng/ml)
and/or various concentrations of 10HDA (20–500mM)
or a single concentration of GM6001 (10mM) at 37Ci n
a humidified atmosphere of 5% CO2. This stimulation
was repeated every 4 days. After 11 days incubation, cells
were fixed with 70% ethanol, then stained with mouse
antihuman CD31 antibody (1:4000) for 1h, and there-
after treated with goat antimouse alkaline phosphatase-
conjugated antibody (1:500) for 1h. Then, BCIP/NBT
solution was applied until endothelial cells were stained
deep purple. Images were collected using a digital camera
(COOLPIX 4500, Nikon, Tokyo, Japan). Tube formation
was estimated by measurements of joints, path, tube
length and tube area using software for tube-formation
analysis (Kurabo). Joints mean that two different tubes
intersect each other. Path means the number of piece
tubes branched from joints. Tube length means the total
length joined each tube together. Tube area means the
total area measured two dimensionally.
Proliferation Assay
HUVECs were seeded at 210
3 cells/well into a 96-well
plate, then incubated for 24h at 37C in a humidified
atmosphere of 5% CO2 (33). HUVECs were rinsed twice
with PBS, then exposed for 6h to HuMedia-EB2 contain-
ing 2% FBS. For stimulation, 10ng/ml VEGF and
20–500mM 10HDA were added, and incubation contin-
ued for 72h. Cell proliferation was estimated by
measuring cell metabolic activity using a Cell Counting
Kit-8 (CCK-8) (Dojindo). CCK-8 measures the rate of
living cells. WST-8, a component of CCK-8, is converted
oxide form of WST-8 by metabolic activity of living cell,
and oxide form of WST-8 shows orange color.
In Vitro Wound-healing Assay
An in vitro wound-healing assay was performed to
measure unidirectional migration by HUVECs (34).
HUVECs were seeded at 410
4cells/well into a 12 well
plate, incubated for 48h at 37C in a humidified
atmosphere of 5% CO2, then washed with PBS twice
and incubated in Humedia-EB2 with 1% FBS. After 24h
incubation, the monolayers of HUVECs were scratch
wounded to a 1mm depth in a straight line using a
10–200ml micro-tip. For stimulation, VEGF (10ng/ml)
and/or 10HDA (500mM) or GM6001 (10mM) were
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were taken at the time of the wounding and at 24-h
intervals thereafter using a phase-contrast microscope
(OLYMPUS, Tokyo, Japan). Migration was estimated by
counting the cell numbers within the wounded region.
Invading cells were counted in a masked fashion by a
single observer (H. I.), and taken as migrating cells. For
each monolayer sample, four measurements were taken
from four fields in each of three independent wounds.
Statistical Analysis
Data are presented as meansSEM Statistical compar-
isons were made using a one-way ANOVA followed by
a Student’s t-test, using STAT VIEW version 5.0 (SAS
Institute, Inc., Cary, NC, USA). A value of P<0.05 was
considered to indicate statistical significance.
Results
VEGF-induced Tube Formation in HUVECs
was Suppressed by 10HDA
We first investigated the effects of 10HDA on endothelial
tube formation. HUVECs and fibroblasts were
co-cultured with VEGF (10ng/ml) and/or various con-
centrations of 10HDA (20–500mM) or GM6001 (10mM).
After 11days incubation, endothelial cells were stained
with anti-CD31 antibody. When treated with VEGF,
HUVECs became organized into complex tubular net-
works (Fig. 1A). All tube-formation parameters (joints,
path, tube length and tube area) were increased more
than 2-fold by VEGF treatment (vs. control) (Fig. 1B).
10HDA decreased VEGF-induced tube formation sig-
nificantly in a concentration-dependent manner. 10HDA
at 20mM or more inhibited the joints and path param-
eters of VEGF-induced tube formation, while 10HDA at
500mM inhibited tube length. However, 10HDA did not
affect tube area at any concentration. On the other hand,
GM6001 at 10mM significantly decreased all tube-
formation parameters. We observed scattered fragments
stained with anti-CD31 antibody in results of tube-
formation assay. The fragments were included in each
one out of five samples in VEGF treatment group,
VEGF and 20mM 10HDA treatment group, VEGF and
500mM 10HDA treatment group. The fragments may be
artifact and we could not explain it, and therefore we
excluded these data included scattered fragments from
statistical processing on in vitro tube-formation assay.
10HDA Prevented Cell Proliferation in HUVECs
Next, we examined whether 10HDA inhibits cell
proliferation in HUVECs. As shown in Fig. 2, treatment
with VEGF (10ng/ml) induced HUVEC proliferation,
the cell count being two times more than in control.
10HDA at 500mM inhibited this VEGF-induced cell
proliferation significantly, however 20–100mM 10HDA
did not inhibit the cell proliferation.
10HDA Suppressed Migration in a Wound-healing Assay
To investigate whether 10HDA inhibits the migration of
HUVECs, we performed a wound-healing assay under
1% FBS conditions (Fig. 3A). Briefly, after starvation,
HUVECs were scratch wounded and treated with VEGF
(10ng/ml) with or without 10HDA (500mM) or GM6001
(10mM). VEGF increased the number of migrated cells
1.76-fold (vs. control). 10HDA and GM6001 reduced this
migration to 86.02.3% (n=6) and 82.14.6%
(n=6), respectively, of the value obtained in the presence
of VEGF (Fig. 3B). However, in the cell migration assay,
we detected no abnormalities with 10HDA or GM6001
alone.
Discussion
In the present study, we showed that 10HDA at 20mMo r
more inhibited VEGF-induced migration, proliferation
and tube formation in HUVECs. On the tube formation
assay, it was expected that 10HDA mainly inhibited cell
migration, because 10HDA inhibited the developmental
step included joints and path and the lengthen step
included tube length. 10HDA at 500mM suppressed both
cell migration (as did GM6001) and proliferation in
HUVECs. These findings indicate that 10HDA may
inhibit the VEGF-induced angiogenesis, partly by inhi-
biting cell migration and proliferation.
In the present study, we used GM6001, a positive
control antiangiogenesis compound, and indeed GM6001
at 10mM inhibited both migration and tube formation in
HUVECs. As far as we know, any one did not report
about the effects that 10HDA inhibits MMP, however
the effects of 10HDA resembled very much with those of
GM6001 on cell migration and in vitro tube formation
assay. Therefore, we cannot rule out the possibility that
10HDA may inhibit MMPs, likely GM6001.
Angiotensin II, which is produced by angiotensin
converting enzyme (ACE), causes hypertension by con-
stricting resistance vessels. RJ peptides [Ile-Tyr (IY),
Val-Tyr (VY), Ile-Val-Tyr (IVY)] have been reported to
exhibit vasodilator and hypotensive activities via inhibi-
tion of ACE (35). Since angiotensin II stimulates
angiogenesis (36) and the migration of retinal micro-
vascular pericytes (37), RJ might be expected to inhibit
angiogenesis by inhibiting angiotensin II. Therefore,
it will be interesting to study whether 10HDA can inhibit
angiotensin II. In the present study, 10HDA inhibited
angiogenesis (tube formation in HUVECs), suggesting
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Figure 1. 10HDA and MMP inhibitor prevented in vitro tube formation in HUVECs. (A) In vitro tube formation was achieved using an in vitro
angiogenesis kit. Briefly, HUVECs and fibroblasts were incubated with VEGF (10ng/ml) (b–f), together with 10HDA (20mM) (c), 10HDA
(100mM) (d), 10HDA (500mM) (e), or GM6001 (10mM) (f). Then 11 days afterwards, they were stained with anti-CD31 antibody, an endothelial cell
marker. Control is shown in (a). Scale bar represents 1mm. (B) Tube formation was evaluated by measurements of joints, path, tube length and tube
area, as described in ‘Methods’. Data represent means and standard error (n=5). ***P<0.01 vs. control; *P<0.05, **P<0.01 vs. vehicle
(Student’s t-test).
492 Inhibition of 10HDA on VEGF-induced angiogenesisthat RJ (which contains 10HDA) could be a useful food
for diseases involving angiogenesis.
We performed this study under restricted conditions,
angiogenesis being examined by evaluating VEGF-
induced tube formation in HUVECs. However, actual
angiogenesis is much more complex. Pro-angiogenic
proteins such as VEGF, fibroblast growth factor (FGF)
and angiopoietin-1 are balanced by antiangiogenic
proteins such as angiopoietin 2, endostatin and tissue
inhibitor of metalloproteinases-1 (TIMP-1). When this
regulation is eliminated or disrupted in such a way that
excessive neovascularization occurs, this may contribute
to the development of tumor growth. Therefore, for
a proper evaluation of the relationship between the anti-
angiogenesis and antitumor growth effects of 10HDA,
future experiments will need to study the effects of RJ
and 10HDA on in vivo angiogenesis models.
In conclusion, this is the first report that 10HDA
inhibits in vitro angiogenesis in HUVECs, in part due to
its inhibition of both cell proliferation and migration.
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